PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA (2013) 20.79

Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology (2012) 4.61

Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res (2004) 3.83

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity (1997) 2.71

Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology (2007) 1.68

Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood (2011) 1.66

Establishment and characterization of an uveal-melanoma cell line. Int J Cancer (1995) 1.59

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54

Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother (2007) 1.47

Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci (2001) 1.41

Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci (2011) 1.37

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer (2013) 1.22

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol (2013) 1.20

Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer (1998) 1.13

Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci U S A (2001) 1.11

A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res (2006) 1.09

Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 1.08

Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res (2006) 1.06

PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin Cancer Res (2011) 1.05

Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer (1997) 1.03

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One (2015) 1.01

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood (2015) 0.98

Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci (1997) 0.97

Current and emerging treatment options for uveal melanoma. Clin Ophthalmol (2013) 0.94

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res (2016) 0.93

Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis (1997) 0.91

Digital PCR validates 8q dosage as prognostic tool in uveal melanoma. PLoS One (2015) 0.88

Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci (2012) 0.87

Clinical Management of Uveal and Conjunctival Melanoma. Oncology (Williston Park) (2016) 0.86

Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy. Int J Cancer (2014) 0.84

A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells. Haematologica (2013) 0.84

Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget (2016) 0.79

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma. Oncotarget (2015) 0.78

HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis. Invest Ophthalmol Vis Sci (2006) 0.77

Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS One (2014) 0.91

Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma. JAMA Ophthalmol (2015) 0.79

Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism. PLoS One (2015) 0.78

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell (2017) 0.76

Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. JAMA Ophthalmol (2016) 0.75